REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
Go back to REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD| Jennison Natural Resources Fund Class B (NASDAQ: RGNX) | Delayed: 8.22 +0.24 (3.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.98 | 52 Week High | $25.00 | |||
| Open | $8.34 | 52 Week Low | $7.07 | |||
| Day High | $8.56 | P/E | N/A | |||
| Day Low | $8.02 | EPS | $0.00 | |||
| Volume | 1,808,112 | |||||
